It is thus crucial to differentiate between MS and NMO because Immunosuppressive drugs (eg, azathioprine and corticosteroids) are regarded as the best treatment for NMO, whereas immunomodulatory treatments (eg, interferon beta and glatiramer acetate) are presently recommended for early treatment of MS. This evidence concerns the gene IFNB1 and neuromyelitis optica.